215 CHURCH STREET, NEW HAVEN, CT
Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
Reports Recent Business Developments and Second Quarter 2026 Financial Results
Director Appointment - John Yetimoglu Joins Biohaven Ltd. Board
Changes in Board, Management or Compensation
Investor Presentation
Amendment No. 2 to Equity Distribution Agreement with J.P. Morgan
Reports Recent Business Developments and First Quarter 2026 Financial Results
2026 Annual Meeting Results; Directors Elected Including Michael T. Heffernan
Q2
Q1
FY 2025
Q3
FY 2024
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Prospectus filed pursuant to Rule 424(b)(7)
Confidential Treatment Order